Investigational Studies

The FDA designates GW Pharmaceuticals’ (GWPH -0.9%) Epidiolex (cannabidiol) an Orphan Drug for the treatment of Tuberous Sclerosis Complex (TSC), a rare genetic condition characterized by the formation of non-malignant tumors in different organs that frequently cause seizures. Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, […]

by

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug designation for cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). TSC is a rare genetic disorder, the most common symptom […]

by

LONDON, April 21, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for cannabidiol (CBD) for the treatment of […]

by

Tweet Send this article by email What is your name? Please indicate below the emails to which you want to send this article: The CBD Story Enter one email per line. No more than 5 emails. Send Close 420 special section By Patrick Maravelias | Weed that doesn’t get you high–what a time to be […]

by

In the live-free world that is considered 2016, the fight for marijuana legalization is bigger than ever. Just last week, Pennsylvania became the 24th state to solidify the use of medical marijuana for selective patients. Business continues to boom for Colorado and celebrities are more vocal with their use, hence, Whoopi Goldberg’s new “canna-business” venture to counter […]

by

Copyright © 2016 Zacks Investment Research At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has nearly tripled the SP 500 […]

by

The FDA recently granted orphan drug designation to a pharmaceutical cannabidiol for the treatment of newborn children with neonatal hypoxic/ischemic encephalopathy, according to a press release from the drug’s manufacturer. An acute or sub-acute brain injury due to asphyxia during the birthing process, neonatal hypoxic/ischemic encephalopathy occurs in 1.5 to 2.8 per 1,000 births in […]

by

So much for making it three days in a row! After posting decent gains both Friday and Monday – especially for Biotech Forum favorites Dynavax Technologies (NASDAQ:DVAX) and Relypsa (NASDAQ:RLYP)– the biotech sector gave it all back and more on Tuesday, dropping almost four percent. Click to enlarge The disaster that one-time darling Valeant Pharmaceuticals […]

by

MEAUX, FRANCE – AUGUST 25: A field of legal cannabis plants selected for their low content of THC grows on August 25, 2014 near Meaux, France. (Photo : Sean Gallup/Getty Images) On Monday, March 14, GW Pharma announced that its cannabis drug, Epidiolex, has proved successful in a late-stage trial. The drug has reduced substantially the number […]

by

Positive results have been reported from a phase 3 study of the investigational medication cannabidiol (Epidiolex, GW Pharmaceuticals) in patients with Dravet syndrome, a rare and debilitating type of infantile-onset epilepsy for which no treatments are currently available in the U.S. Cannabidiol achieved the trial’s primary endpoint of a significant reduction in convulsive seizures assessed […]

by